MedPacto Obtains Patent Related to BAG2 Polypeptide
[Asia Economy Reporter Minwoo Lee] MedPacto announced on the 13th that it has obtained a patent for an "antibody or its antigen-binding fragment that specifically binds to BAG2 polypeptide or its fragment."
Through this patent, it was discovered that the BAG2 protein is secreted outside the cell via interaction with the protease cathepsin B during the carcinogenesis process, and it was confirmed that the loss of BAG2 protein completely suppresses tumor formation and lung metastasis in a breast cancer animal model.
Hot Picks Today
!["Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026051507261063923_1778797570.png)
"Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Sold Out Everywhere" The Surprising Story of the 'Purple Gold' Philippine Yam That Has Captivated the World [Delicious Stories]
- While All Eyes Were on Samsung and Hynix, This Company Surged 50% to New Highs in Four Days [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
MedPacto stated, "Using this patent, we are developing an antibody therapeutic (MA-B2) targeting various cancers, including breast cancer, in which BAG2 is overexpressed."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
